Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Rikke F, Andersen"'
Autor:
Caroline B. Thomsen, Torben F. Hansen, Rikke F. Andersen, Jan Lindebjerg, Lars H. Jensen, Anders Jakobsen
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: The early identification of treatment effect is wanted in several settings, including the management of metastatic colorectal cancer (mCRC). A potential universal marker is circulating tumor DNA (ctDNA). Our prospective study explored the
Externí odkaz:
https://doaj.org/article/7691c5fcc85d4275bf673f1042e721cd
Autor:
Caroline Brenner Thomsen, Ivan Brandslund, Dorte Aa. Olsen, Jonna Skov Madsen, Rikke F. Andersen, Anders Jakobsen
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Scientific Reports
Olsen, D A, Thomsen, C E B, Andersen, R F, Madsen, J S, Jakobsen, A & Brandslund, I 2020, ' Decreased concentrations of intracellular signaling proteins in colon cancer patients with BRAF mutations ', Scientific Reports, vol. 10, 20113 . https://doi.org/10.1038/s41598-020-77109-8
Scientific Reports
Olsen, D A, Thomsen, C E B, Andersen, R F, Madsen, J S, Jakobsen, A & Brandslund, I 2020, ' Decreased concentrations of intracellular signaling proteins in colon cancer patients with BRAF mutations ', Scientific Reports, vol. 10, 20113 . https://doi.org/10.1038/s41598-020-77109-8
The activation of intracellular signaling pathways plays a critical role in cancer pathogenesis. The current study aims to quantify intracellular signaling proteins in localized colon cancer tissue to investigate the prognostic value of these biomark
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49b99b9fe35e5841e55ace463d0d950b
http://link.springer.com/article/10.1038/s41598-020-77109-8
http://link.springer.com/article/10.1038/s41598-020-77109-8
Publikováno v:
Appelt, A L, Andersen, R F, Lindebjerg, J & Jakobsen, A 2020, ' Prognostic Value of Serum NPY Hypermethylation in Neoadjuvant Chemoradiotherapy for Rectal Cancer : Secondary Analysis of a Randomized Trial ', American Journal of Clinical Oncology, vol. 43, no. 1, pp. 9-13 . https://doi.org/10.1097/COC.0000000000000609
Objectives: Long-term prevention of metastatic disease remains a challenge in locally advanced rectal cancer, and robust pretreatment prognostic factors for metastatic progression are lacking. We hypothesized that detecting circulating tumor-specific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f82db5312749e27a96aa68c3874e25d
https://doi.org/10.1097/coc.0000000000000609
https://doi.org/10.1097/coc.0000000000000609
Autor:
Parvin Adimi, Marianne Waldstrøm, Anders Jakobsen, Mads Kingo Guldberg Hansen, Maja Patricia Smerdel, Karina Dahl Steffensen, Rikke F. Andersen
Publikováno v:
Hansen, M K G, Smerdel, M P, Waldstrøm, M, Andersen, R F, Adimi, P, Jakobsen, A & Steffensen, K D 2020, ' Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients ', Cancer Chemotherapy and Pharmacology, vol. 86, pp. 751-759 . https://doi.org/10.1007/s00280-020-04162-5
Purpose: Treatment of multi-resistant epithelial ovarian cancer represents a clinical challenge with limited choices. Anti-angiogenic therapy has shown great potential in combination with frontline-therapy. Studies investigating heavily pre-treated p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c5d28083a9b2363f52aa0f76c0956ff
https://pubmed.ncbi.nlm.nih.gov/33067703
https://pubmed.ncbi.nlm.nih.gov/33067703
Autor:
Matthew G. Cottingham, Rikke F. Andersen, Alexandra J. Spencer, Saroj Saurya, Julie Furze, Adrian V. S. Hill, Sarah C. Gilbert
Publikováno v:
PLoS ONE, Vol 6, Iss 2 (2011)
Externí odkaz:
https://doaj.org/article/f72d79b480f94d1ea79bd29e52d025c4
Autor:
Matthew G Cottingham, Rikke F Andersen, Alexandra J Spencer, Saroj Saurya, Julie Furze, Adrian V S Hill, Sarah C Gilbert
Publikováno v:
PLoS ONE, Vol 3, Iss 2, p e1638 (2008)
The production, manipulation and rescue of a bacterial artificial chromosome clone of Vaccinia virus (VAC-BAC) in order to expedite construction of expression vectors and mutagenesis of the genome has been described (Domi & Moss, 2002, PNAS99 12415-2
Externí odkaz:
https://doaj.org/article/a58c3e88c42e420fbe8b9b750ad4f853
Publikováno v:
Rusan, M, Andersen, R F, Jakobsen, A & Steffensen, K D 2020, ' Circulating HOXA9-methylated tumour DNA : A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer ', European journal of cancer (Oxford, England : 1990), vol. 125, pp. 121-129 . https://doi.org/10.1016/j.ejca.2019.11.012
Rusan, M, Andersen, R F, Jakobsen, A & Steffensen, K D 2020, ' Circulating HOXA9-methylated tumour DNA : A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer ', European Journal of Cancer, vol. 125, pp. 121-129 . https://doi.org/10.1016/j.ejca.2019.11.012
Rusan, M, Andersen, R F, Jakobsen, A & Steffensen, K D 2020, ' Circulating HOXA9-methylated tumour DNA : A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer ', European Journal of Cancer, vol. 125, pp. 121-129 . https://doi.org/10.1016/j.ejca.2019.11.012
AIM: Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as a novel treatment option in BRCA-mutated ovarian cancer (OC); however, responses are variable and there is a lack of prognostic and predictive biomarkers. We therefore investigated w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dc665a9ffc6128f2a28c82d7a753d3e
https://portal.findresearcher.sdu.dk/da/publications/fccb5999-44cc-4230-823e-06cc69b1846b
https://portal.findresearcher.sdu.dk/da/publications/fccb5999-44cc-4230-823e-06cc69b1846b
Autor:
Torben Hansen, Jan Lindebjerg, John Pløen, Anders Jakobsen, Lise Nottelmann, Eva Fernebro, Lene Byriel, Lars Henrik Jensen, Rikke F. Andersen
Publikováno v:
Jensen, L H, Andersen, R F, Byriel, L, Fernebro, E, Jakobsen, A, Lindebjerg, J, Nottelmann, L, Ploen, J & Hansen, T F 2020, ' Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers ', Acta oncologica (Stockholm, Sweden), vol. 59, no. 3, pp. 298-301 . https://doi.org/10.1080/0284186X.2019.1701201
Background: Molecular markers may identify subgroups of patients with clinically distinct behavior and response to treatment. In some gastrointestinal tumors, KRAS has prognostic value and negative predictive value. This is the first prospective stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3de678a70b042a92af30048dc421aea
Autor:
Torben Hansen, Jan Lindebjerg, Caroline Brenner Thomsen, Rikke F. Andersen, Lars Henrik Jensen, Anders Jakobsen
Publikováno v:
Therapeutic Advances in Medical Oncology
Thomsen, C B, Hansen, T F, Andersen, R F, Lindebjerg, J, Jensen, L H & Jakobsen, A 2020, ' Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer ', Therapeutic Advances in Medical Oncology, vol. 12, pp. 1-7 . https://doi.org/10.1177/1758835920918472
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Thomsen, C B, Hansen, T F, Andersen, R F, Lindebjerg, J, Jensen, L H & Jakobsen, A 2020, ' Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer ', Therapeutic Advances in Medical Oncology, vol. 12, pp. 1-7 . https://doi.org/10.1177/1758835920918472
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: The early identification of treatment effect is wanted in several settings, including the management of metastatic colorectal cancer (mCRC). A potential universal marker is circulating tumor DNA (ctDNA). Our prospective study explored the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1602583abab27510cf080532c9c3a026
https://pubmed.ncbi.nlm.nih.gov/32518596
https://pubmed.ncbi.nlm.nih.gov/32518596
Autor:
Torben Hansen, Lars Henrik Jensen, Rikke F. Andersen, Anders Jakobsen, Jan Lindebjerg, Caroline Brenner Thomsen
Publikováno v:
Thomsen, C B, Andersen, R F, Lindebjerg, J, Hansen, T F, Jensen, L H & Jakobsen, A 2019, ' Correlation between tumor-specific mutated and methylated DNA in colorectal cancer ', JCO Precision Oncology, vol. 3, pp. 1-8 . https://doi.org/10.1200/PO.18.00162
PURPOSE Analysis of circulating tumor DNA (ctDNA) is a potential improvement in precision medicine. In colorectal cancer (CRC), somatic mutations such as RAS and RAF in the blood (mut-ctDNA) are investigated for prognostic and predictive purposes. Ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67e00c941ccbea980699abf0d1b48abc
https://findresearcher.sdu.dk:8443/ws/files/168819490/JCO_Precision_Oncology.pdf
https://findresearcher.sdu.dk:8443/ws/files/168819490/JCO_Precision_Oncology.pdf